Kineteks

Kinetek Pharmaceuticals was a Vancouver-based biotechnology company specializing in the discovery and development of small molecule drugs that target protein kinases. The company leveraged a proprietary proteomics platform to identify signaling pathways involved in serious conditions such as cancer, diabetes, and inflammation. Its lead candidate, an integrin-linked kinase (ILK) inhibitor, was advanced into early-stage clinical trials for oncology indications. Kinetek's approach focused on the kinome, aiming to modulate specific enzymes to restore normal cellular function. In 2004, the company was acquired by QLT Inc., integrating its kinase expertise and pipeline into QLT's broader portfolio.